KR102310387B1 - 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의 병용물 - Google Patents

그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의 병용물 Download PDF

Info

Publication number
KR102310387B1
KR102310387B1 KR1020147034614A KR20147034614A KR102310387B1 KR 102310387 B1 KR102310387 B1 KR 102310387B1 KR 1020147034614 A KR1020147034614 A KR 1020147034614A KR 20147034614 A KR20147034614 A KR 20147034614A KR 102310387 B1 KR102310387 B1 KR 102310387B1
Authority
KR
South Korea
Prior art keywords
antibiotic
plyss2
combination
daptomycin
antibiotics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147034614A
Other languages
English (en)
Korean (ko)
Other versions
KR20150035587A (ko
Inventor
레이몬드 슈
로버트 씨. 노윈스키
마이클 위터킨드
한 이
브렌트 슈나이더
Original Assignee
콘트라펙트 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 콘트라펙트 코포레이션 filed Critical 콘트라펙트 코포레이션
Priority to KR1020217031525A priority Critical patent/KR20210121313A/ko
Publication of KR20150035587A publication Critical patent/KR20150035587A/ko
Application granted granted Critical
Publication of KR102310387B1 publication Critical patent/KR102310387B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Paints Or Removers (AREA)
KR1020147034614A 2012-05-09 2013-05-09 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의 병용물 Expired - Fee Related KR102310387B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217031525A KR20210121313A (ko) 2012-05-09 2013-05-09 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의 병용물

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261644944P 2012-05-09 2012-05-09
US61/644,944 2012-05-09
US201261737239P 2012-12-14 2012-12-14
US61/737,239 2012-12-14
PCT/US2013/040329 WO2013170015A1 (en) 2012-05-09 2013-05-09 Bacteriophage lysin and antibiotic combinations against gram positive bacteria

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217031525A Division KR20210121313A (ko) 2012-05-09 2013-05-09 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의 병용물

Publications (2)

Publication Number Publication Date
KR20150035587A KR20150035587A (ko) 2015-04-06
KR102310387B1 true KR102310387B1 (ko) 2021-10-13

Family

ID=49551273

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020147034614A Expired - Fee Related KR102310387B1 (ko) 2012-05-09 2013-05-09 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의 병용물
KR1020237023634A Withdrawn KR20230113404A (ko) 2012-05-09 2013-05-09 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의병용물
KR1020217031525A Ceased KR20210121313A (ko) 2012-05-09 2013-05-09 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의 병용물

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020237023634A Withdrawn KR20230113404A (ko) 2012-05-09 2013-05-09 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의병용물
KR1020217031525A Ceased KR20210121313A (ko) 2012-05-09 2013-05-09 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의 병용물

Country Status (16)

Country Link
US (5) US10813983B2 (enExample)
EP (2) EP2849782B1 (enExample)
JP (4) JP6608697B2 (enExample)
KR (3) KR102310387B1 (enExample)
CN (1) CN104736172A (enExample)
AU (3) AU2013259512B2 (enExample)
BR (1) BR112014027842A2 (enExample)
CA (1) CA2872902A1 (enExample)
DK (1) DK2849782T3 (enExample)
ES (1) ES2784136T3 (enExample)
HK (1) HK1211484A1 (enExample)
IL (3) IL308477A (enExample)
IN (1) IN2014MN02437A (enExample)
MX (2) MX389127B (enExample)
RU (2) RU2659208C2 (enExample)
WO (1) WO2013170015A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102310387B1 (ko) 2012-05-09 2021-10-13 콘트라펙트 코포레이션 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의 병용물
CA3187222A1 (en) 2012-05-09 2013-11-14 Contrafect Corporation Biofilm prevention, disruption and treatment with bacteriophage lysin
CN106659748B (zh) * 2014-06-26 2021-08-31 洛克菲勒大学 不动杆菌属溶素
WO2016142445A2 (en) * 2015-03-12 2016-09-15 Micreos Human Health B.V. A method of treatment of a bacterial infection
EP4151228A3 (en) 2015-09-17 2023-06-14 Contrafect Corporation Lysin polypeptides active against gram-negative bacteria
CA3023730A1 (en) * 2016-05-12 2017-11-16 Contrafect Corporation Broth microdilution method for evaluating and determining minimal inhibitory concentration of antibacterial polypeptides
CA3067542A1 (en) * 2017-06-19 2018-12-27 Syddansk Universitet Bacitracin and/or daptomycin combined with cannabidiol for treatment of bacterial infections
AU2018300062A1 (en) * 2017-07-10 2020-01-30 Contrafect Corporation Blood component potentiation of lytic protein anti-bacterial activity and methods and uses thereof
CN112118861A (zh) * 2018-02-26 2020-12-22 康特拉费克特公司 修饰的PlySs2溶素及其用途
EP3809851A4 (en) * 2018-06-22 2022-03-23 Contrafect Corporation Lysins and derivatives thereof resensitize staphylococcus aureus and gram-positive bacteria to antibiotics
CN109668873B (zh) * 2018-12-05 2021-03-16 山东恒业生物技术有限公司 一种活载体疫苗活性检测装置及其使用方法
BR112021015289A2 (pt) * 2019-02-05 2021-10-05 Elanco Us Inc. Composição, método para melhorar saúde animal, e, método para tratar, melhorar os efeitos ou prevenir a enterite necrótica em aves
AU2020244764A1 (en) * 2019-03-22 2021-10-14 Contrafect Corporation Method of treating infective endocarditis
EP3980049A4 (en) * 2019-04-11 2023-07-19 Contrafect Corporation METHOD OF TREATMENT AND PREVENTION OF BONE AND JOINT INFECTIONS
US20230105108A1 (en) * 2019-12-19 2023-04-06 Georgia State University Research Foundation, Inc. Compounds for the treatment of bacterial infections and potentiation of antibiotics
EP4157306A4 (en) * 2020-05-19 2024-07-03 Contrafect Corporation MODIFIED PLYSS2 LYSINES AND ANTIBIOTIC COMBINATIONS FOR USE AGAINST GRAM-POSITIVE BACTERIA
RU2755817C1 (ru) * 2020-07-22 2021-09-21 Федеральное Государственное бюджетное научное учреждение "Федеральный научный центр биологических систем и агротехнологий российской академии наук" Способ снижения грамположительной микрофлоры в кишечнике птицы
KR102528412B1 (ko) * 2020-09-08 2023-05-04 클립스비엔씨 주식회사 신규한 포도상구균 감염 질환의 예방 또는 치료용 조성물
WO2022261360A1 (en) * 2021-06-09 2022-12-15 Contrafect Corporation Plyss2 lysins and variants thereof for use against multidrug resistant gram-positive bacteria
CN115105491B (zh) * 2022-07-08 2023-12-22 东北农业大学 丝氨酸在制备抑制猪链球菌药物中的用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8108587A (en) 1986-10-08 1988-05-06 David Bernstein Method for exposing group a streptococcal antigens and an improved diagnostic test for the identification of group a streptococci
ZA883887B (en) 1987-06-10 1990-02-28 Lilly Co Eli Chromatographic purification process
CA2251724A1 (en) * 1996-04-15 1997-10-23 Paul Averback Compositions containing bacteriophages and methods of using bacteriophages to treat infections
US5997862A (en) 1997-10-31 1999-12-07 New Horizons Diagnostics Corporation Therapeutic treatment of group A streptococcal infections
US6264945B1 (en) 1997-10-31 2001-07-24 Vincent A Fischetti Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections
US6254866B1 (en) 1997-10-31 2001-07-03 New Horizons Diagnostics Corporation Use of phage associated lytic enzymes for treating bacterial infections of the digestive tract
US6248324B1 (en) 1997-10-31 2001-06-19 Vincent Fischetti Bacterial phage associated lysing enzymes for treating dermatological infections
US20060292135A1 (en) 1997-10-31 2006-12-28 Lawrence Loomis Use of bacterial phage-associated lysing proteins for preventing and treating bacterial infections in humans, animals and fowl
CA2366712A1 (en) 1999-02-25 2000-08-31 Vincent Fischetti A means for the prophylactic and therapeutic treatment of streptococcal infections
US6056955A (en) 1999-09-14 2000-05-02 Fischetti; Vincent Topical treatment of streptococcal infections
US6444813B2 (en) 2000-02-02 2002-09-03 Pharmacia & Upjohn Company Linezolid-crystal form II
EP1501925A4 (en) 2002-05-17 2006-10-25 New Horizons Diagnostics Corp IDENTIFICATION OF A LYTIC ENZYME ASSOCIATED WITH A PHAGE TO DETECT AND ELIMINATE RAPIDLY AND SPECIFICALLY BACILLUS ANTHRACIS
US7569223B2 (en) 2004-03-22 2009-08-04 The Rockefeller University Phage-associated lytic enzymes for treatment of Streptococcus pneumoniae and related conditions
WO2005089527A2 (en) 2004-03-24 2005-09-29 The Rockefeller University Lytic enzymes and spore surface antigen for detection and treatment of bacillus anthracis bacteria and spores
WO2008018854A2 (en) 2005-06-06 2008-02-14 The Rockefeller University Bactiophage lysins for bacillus anthracis
US7582291B2 (en) 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
ATE491026T1 (de) 2005-08-24 2010-12-15 Univ Rockefeller Ply-gbs-lysinmutanten
WO2009029192A1 (en) 2007-08-24 2009-03-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Surfactant-based antimicrobial solution for inhalation
EP3263588A1 (en) 2008-07-03 2018-01-03 The Rockefeller University Isolated staphylococcus-specific soluble binding molecule
KR101016918B1 (ko) 2009-01-08 2011-02-25 주식회사 인트론바이오테크놀로지 박테리아 특이적 넓은 항균 활성을 갖는 신규한 리신 단백질
WO2011091412A1 (en) 2010-01-25 2011-07-28 Alere Scarborough, Inc. A25 bacteriophage lysin
US20120271770A1 (en) * 2011-04-20 2012-10-25 Visa International Service Association Managing electronic tokens in a transaction processing system
US20140179594A1 (en) 2011-04-21 2014-06-26 The Rockefeller University Streptococcus bacteriophage lysins for treatment of gram positive bacteria in companion animals and livestock
DK2699253T3 (en) * 2011-04-21 2018-07-16 Univ Rockefeller STREPTOCOCCUS BACTERYPHAGIC LYSINES FOR THE DETECTION AND TREATMENT OF GRAM POSITIVE BACTERIES
WO2012145693A1 (en) 2011-04-22 2012-10-26 Rks Design, Inc. Instrument retention assembly
EP2993181A1 (en) 2011-04-27 2016-03-09 Lysando AG New antimicrobial agents
KR102310387B1 (ko) 2012-05-09 2021-10-13 콘트라펙트 코포레이션 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의 병용물
CA3187222A1 (en) * 2012-05-09 2013-11-14 Contrafect Corporation Biofilm prevention, disruption and treatment with bacteriophage lysin

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Antimicrobial Agents and Chemotherapy. Vol. 54, no. 4, pp. 1603-1612 (2010)*
Bioengineered Bugs. Vol. 1, No. 1, pp. 9-16 (2010)
Current Opinion in Microbiology. Vol. 11, pp. 393-400 (2008)
Jonathan Edward Schmitz. Expanding the Horizons of Enzybiotic Identification. Rockefeller University 박사학위논문 (2011)*

Also Published As

Publication number Publication date
ES2784136T3 (es) 2020-09-22
IL235527A0 (en) 2015-01-29
CN104736172A (zh) 2015-06-24
HK1208799A1 (en) 2016-03-18
US20180221456A1 (en) 2018-08-09
US20150290299A1 (en) 2015-10-15
JP2018138045A (ja) 2018-09-06
US10813983B2 (en) 2020-10-27
RU2014149351A (ru) 2016-07-10
MX2014013586A (es) 2015-06-05
US9889181B2 (en) 2018-02-13
EP3685851A1 (en) 2020-07-29
JP2022058682A (ja) 2022-04-12
DK2849782T3 (da) 2020-06-22
US20210008175A1 (en) 2021-01-14
KR20210121313A (ko) 2021-10-07
AU2013259512B2 (en) 2018-01-25
WO2013170015A1 (en) 2013-11-14
JP2015523964A (ja) 2015-08-20
RU2659208C2 (ru) 2018-06-28
JP2020054370A (ja) 2020-04-09
US20130302306A1 (en) 2013-11-14
AU2020233683A1 (en) 2020-10-08
KR20150035587A (ko) 2015-04-06
JP6608697B2 (ja) 2019-11-20
IL308477A (en) 2024-01-01
MX389127B (es) 2025-03-19
CA2872902A1 (en) 2013-11-14
IL274832A (en) 2020-07-30
US20210128696A1 (en) 2021-05-06
MX2021011843A (es) 2021-10-22
BR112014027842A2 (pt) 2017-08-08
IN2014MN02437A (enExample) 2015-07-10
HK1211484A1 (en) 2016-05-27
AU2018202845B2 (en) 2020-06-18
EP2849782A4 (en) 2016-01-20
EP2849782B1 (en) 2020-03-18
KR20230113404A (ko) 2023-07-28
EP2849782A1 (en) 2015-03-25
IL235527B1 (en) 2023-06-01
AU2013259512A1 (en) 2014-12-11
AU2018202845A1 (en) 2018-05-10
RU2018121290A (ru) 2019-03-06
IL235527B2 (en) 2023-10-01

Similar Documents

Publication Publication Date Title
KR102310387B1 (ko) 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의 병용물
US20230277617A1 (en) Biofilm prevention, disruption and treatment with bacteriophage lysin
HK40033231A (en) Bacteriophage lysin and antibiotic combinations against gram positive bacteria
HK1208799B (en) Bacteriophage lysin and antibiotic combinations against gram positive bacteria

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20241002

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20241002

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20241002